Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05238649
Recruitment Status : Active, not recruiting
First Posted : February 14, 2022
Last Update Posted : March 29, 2022
Sponsor:
Information provided by (Responsible Party):
Livzon Pharmaceutical Group Inc.

Brief Summary:
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

Condition or disease Intervention/treatment Phase
COVID-19 Pandemic Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg Biological: SARS-Cov-2 Vaccine Inactivated Phase 2

Detailed Description:

This is a Randomized, Double Blind, Positive Control exploratory clinical study. 150 participants aged 18 years and older who have completed the 2 doses of administration of inactive vaccines 6 months (±1 month) ago were enrolled in this study to evaluate the safety and immunogenicity of V-01.

The participants will be enrolled to test group A (V-01 10 μg), test group B (V-01 25 μg) and test group C (inactivated vaccine) by the ratio of 1:1:1. The participants received 1 dose of V-01 or inactivated vaccine base on the group.

The random stratification factor is age (18-59 years old vs. ≥ 60 years old).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Actual Study Start Date : November 10, 2021
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : January 28, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: V-01 10 μg
10 μg(0.5ml)/vial, one dose administrated by intramuscular injection
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg
The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Other Name: V-01 10μg

Experimental: V-01 25 μg
25 μg(0.5ml)/vial, one dose administrated by intramuscular injection
Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg
The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Other Name: V-01 25μg

Active Comparator: Inactivated vaccine
0.5ml/vial, containing 100U inactivated COVID-19 virus antigen. One dose administrated by intramuscular injection
Biological: SARS-Cov-2 Vaccine Inactivated
The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Other Name: Inactivated vaccine




Primary Outcome Measures :
  1. Geometric Mean Titers of SARS-CoV-2 neutralizing antibodies [ Time Frame: 28 days after booster immunization ]
    The Geometric Mean Titers of SARS-CoV-2 neutralizing antibodies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy participants aged 18 years and older who have completed the second dose of 2-dose regimen of SARS-CoV-2 Inactivated Vaccine in the past 6 (±1) months;
  2. Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
  3. In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
  4. Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.

Exclusion Criteria:

1. Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR. 2. History of previous SARS infection. 3. History of severe allergy to any vaccine or any ingredient of the vaccine including aluminum adjuvant, e.g., anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), dyspnea, angioedema, etc.

4. People who currently suffer from the following diseases:

  1. Symptoms related to acute respiratory infections (such as: sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.)
  2. Patients with thrombocytopenia, any coagulation dysfunction, or receive anticoagulant treatment, etc.
  3. Patients with congenital or acquired angioedema/neuroedema;
  4. A history of congenital or acquired immunodeficiency or autoimmune disease (except for mild psoriasis, controllable autoimmune thyroid disease, vitiligo, or stable celiac disease that does not require immunosuppressive or immunomodulatory therapy); no spleen , or history of spleen surgery, history of trauma, or treatment with immunomodulators within 6 months, such as: glucocorticoid with the dose causing immunosuppressive (dose reference: equivalent to prednisone 20mg/day, more than one week); or monoclonal antibody ; or thymosin; or interferon, etc.; but local medication (such as ointment, eye drops, inhalation or nasal spray) is allowed.
  5. Patients with active tuberculosis, viral hepatitis, human immunodeficiency virus or syphilis infection.
  6. Patients with acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases: history of chronic respiratory diseases (including moderate to severe asthma, COPD, pulmonary fibrosis), hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmHg) And/or diastolic blood pressure ≥100mmHg), history of severe cardiovascular disease (including heart failure, coronary artery disease, cardiomyopathy), history of chronic kidney disease, history of cancer (except for basal cell carcinoma), diabetes (unsatisfied blood sugar control or diabetes related serious complications).

5. Received inactivated vaccines or any subunit vaccines within 14 days before the vaccination and attenuated live vaccine within 28 days before the vaccination.

6. Injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; or with the plan to use such product within 6 month after immunization.

7. Pregnant (including positive urine pregnancy test for women of childbearing age) or breastfeeding women. Or women or their partners who have a pregnancy plan within 3 months after the trial vaccination.

8. Have participated in or are participating in other COVID-19 related clinical trials, or are participating in other drug clinical trials; 9. Those considered by the investigator as inappropriate to participate in the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05238649


Locations
Layout table for location information
China, Guangdong
Zhuhai Peoples' Hospital Medical Group
Zhuhai, Guangdong, China, 519000
Sponsors and Collaborators
Livzon Pharmaceutical Group Inc.
Investigators
Layout table for investigator information
Principal Investigator: Ligong Lu, Dr. Zhuhai People's Hospital Medical Group
Layout table for additonal information
Responsible Party: Livzon Pharmaceutical Group Inc.
ClinicalTrials.gov Identifier: NCT05238649    
Other Study ID Numbers: ICV-V-01-Booster-A
First Posted: February 14, 2022    Key Record Dates
Last Update Posted: March 29, 2022
Last Verified: March 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs